If you have an ad-blocker enabled you may be blocked from proceeding. VICTORIA, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) — Emerald Health Therapeutics, Inc. (TSXV:EMH) (“Emerald” or the “Company”) has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Lead Investor”) under which the Lead Investor has agreed, subject to certain customary conditions, to purchase 4,000,000 common shares of the Company (the “Common Shares”) at a price of $2.70 per Common Share for gross proceeds of $10,800,000 (the “Offering”). #5 The NCV Newswire is hand-curated by an editor and not automated in anyway. Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Our story Emerald Health Sciences (Emerald) is a global leader in the life science industry focused on building companies advancing the development of cannabis and cannabinoids in the pharmaceutical, botanical, and bioceutical applications for the enhancement of health and well-being. Of the total figure issued, $794,182 is related to a previously entered loan agreement whereas the remainder is in relation to trade payables. EMH | Complete Emerald Health Therapeutics Inc. stock news by MarketWatch. ft … View daily, weekly or … Emerald’s Richmond operation has been designed for health and wellness-oriented organic cannabis cultivation and consists of a 78,000 sq. The Offering may be increased by an additional 600,000 Common Shares for total aggregate gross proceeds of up to $12,420,000. Emerald… Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013. Please disable your ad-blocker and refresh. invest@emeraldhealth.ca. In total, $2,816,963 in debt will be settled via the transaction, which will see 9,713,666 common shares of Emerald Health Therapeutics issued to Emerald Sciences at a price of $0.29. The Company intends to use the net proceeds of the Offering to fund the completion of capital projects, research and development, working capital, and general corporate purposes. (800) 757 3536 Ext. Visit our Investors page for the latest news releases, stock information, financial reports and more – everything you need to know to invest with confidence. (800) 757 3536 Ext. Find the latest EMERALD HEALTH THERAPEUTICS INC (EMHTF) stock quote, history, news and other vital information to help you with your stock trading and investing. Company profile page for Emerald Health Sciences Inc including stock price, company news, press releases, executives, board members, and contact information Its 50%-owned Pure Sunfarms joint venture in BC is completing a sophisticated 1.1 million square feet greenhouse and its Agro-Biotech operation in Québec is completing a 75,000 square feet indoor facility. Emerald Health Sciences (Emerald) is a global leader in the life science industry focused on building companies advancing the development of cannabis and cannabinoids in the pharmaceutical, botanical, and bioceutical applications for the enhancement of health and well-being.